If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


ACS News

CAS curates data set of antiviral compound

by Linda Wang
April 18, 2020 | A version of this story appeared in Volume 98, Issue 15

To help accelerate the development of antiviral therapies against COVID-19, CAS, a division of the American Chemical Society, has curated a data set of nearly 50,000 chemical substances with known or potential antiviral activity that could serve as potential leads. The data set, which CAS has made publicly available through open access, was curated from the CAS Registry of more than 160 million chemical substances.

“We have this wealth of knowledge that we’re sitting on—these databases in science that we’ve built for the last 113 years—and we want to open up key parts of it to help accelerate treatments and/or vaccines to COVID-19,” says Michael Dennis, vice president for innovation at CAS.

Dennis says the idea for this data set came out of two tables in a recent publication by CAS in ACS Central Science that included antiviral and small molecules with potential therapeutic applications against COVID-19 (DOI: 10.1021/acscentsci.0c00272). The article has already received more than 200,000 views, and CAS wanted to expand this resource.

Using SciFindern and other tools, algorithms, and models, “we started compiling a list of 100-plus compounds with known antiviral activity as reported in the literature,” such as remdesivir, Dennis says. “We then found many similar compounds and distilled them down to 50,000 candidate compounds by biological activity, such as anti-infective agents, respiratory systems agents, and enzyme inhibitors.”

CAS has also deposited this data set to the Allen Institute for AI’s COVID-19 Open Research Dataset to support the recent White House Office of Science and Technology Policy call to support COVID-19 research for treatments and vaccines.

Dennis says this is the first of several data sets that CAS is curating to help with the discovery of new treatments for COVID-19.

CAS president Manuel Guzman says that “CAS is fully committed to leveraging our content, technology, and expertise in every way possible” to support researchers and health-care professionals on the front lines of fighting this disease.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.